Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNP622
- Development stage
- Preclinical
- Lead developer
- SciNeuro Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
SNP622 is an antisense oligonucleotide (ASO) therapeutic candidate developed by SciNeuro Pharmaceuticals for the treatment of Alzheimer's disease. It is designed to target Apolipoprotein E (ApoE), specifically the APOE4 isoform, which is recognized as the most significant genetic risk factor for the development of late-onset Alzheimer's. By binding to ApoE mRNA, SNP622 facilitates its degradation, thereby reducing the levels of the ApoE4 protein in the brain. This reduction is intended to decrease amyloid-beta aggregation and neurotoxicity, potentially slowing or halting disease progression. The program is currently in preclinical development.
02
Targets
APOE (Apolipoprotein E)
Beyond the preview
Go deeper on SNP622.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNP622.